“Mantell Associates was a pleasure to work with! From their attention to detail, proactive approach and enthusiasm for the hiring process, I cannot recommend them highly enough. You can tell that they genuinely care. Thanks to the team for a wonderful experience.”
VP of Business Development
Mantell Associates recently appointed Tarran Pierfelice as CCO at Cellistic. Tarran has over a decade of experience in biopharma and a remarkable history of building strategic partnerships, bringing a wealth of expertise to propel Cellistic’s growth and redefine what’s possible in advanced therapies.
Launched in April 2022, Cellistic specializes in process development and manufacture of cell therapies based on human induced pluripotent stem cell (iPSC) technology. The company’s focus and expertise in iPSC generation and differentiation protocol development makes it well-positioned to partner with innovative cell therapy developers to establish novel advanced therapies. With more than a decade of scientific and technical knowledge transfer from sister company Ncardia, Cellistic is uniquely experienced in designing and optimizing manufacturing procedures for iPSCs that deliver quality products at scale.
Company website – https://www.cellistic.com/
To find out more about Cellistic, contact Fernand Desjarlais on +44 (0)20 3854 7700 or fernand.desjarlais@mantellassociates.com.